Recruiting
Chronic lymphocytic leukaemia refractory+13
RecruitingStudy of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies
Registered drugNo placebo
Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies
Registered drugNo placebo
- Disease:Chronic lymphocytic leukaemia refractoryChronic lymphocytic leukaemia recurrent+12
- Substances:BGB-16673Glofitamab+4
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:BGB-16673
- Sponsor:BeOne Medicines AG


